• +1-646-491-9876
    • +91-20-67278686

    Search

    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017

    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017

    • Report Code ID: RW0001689432
    • Category Healthcare
    • No. of Pages 207
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

    Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 17, 7, 18 and 1 respectively. Similarly, the Universities portfolio in IND/CTA Filed and Discovery stages comprises 1 and 1 molecules, respectively.

    Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
    - The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 8
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 22
    Assessment by Route of Administration 25
    Assessment by Molecule Type 27
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 29
    advanceCor GmbH 29
    Akcea Therapeutics Inc 29
    Amarantus Bioscience Holdings Inc 30
    AnGes MG Inc 30
    Arena Pharmaceuticals Inc 31
    Ascendia Pharmaceuticals LLC 31
    AstraZeneca Plc 32
    Athera Biotechnologies AB 32
    Bayer AG 33
    Biscayne Pharmaceuticals Inc 33
    Capricor Therapeutics Inc 34
    Cardiome Pharma Corp 34
    CardioVascular BioTherapeutics Inc 35
    Cerenis Therapeutics Holding SA 35
    CSL Ltd 36
    Esperion Therapeutics Inc 36
    Gilead Sciences Inc 37
    HitGen LTD 37
    Human Stem Cells Institute 38
    Japan Tobacco Inc 38
    Juventas Therapeutics Inc 39
    Lee's Pharmaceutical Holdings Ltd 39
    LipimetiX Development Inc 40
    Lonestar Heart Inc 40
    MedImmune LLC 41
    Merck & Co Inc 41
    Nuo Therapeutics Inc 42
    Pfizer Inc 42
    Pharmahungary Group 43
    Proteon Therapeutics Inc 43
    Resverlogix Corp 44
    Tasly Pharmaceutical Group Co Ltd 44
    The Medicines Company 45
    Verseon Corp 45
    VESSL Therapeutics Ltd 46
    ViroMed Co Ltd 46
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles 47
    4-WF - Drug Profile 47
    AEM-28 - Drug Profile 48
    AEM-2802 - Drug Profile 50
    ALD-201 - Drug Profile 51
    alprostadil - Drug Profile 53
    AMRS-001 - Drug Profile 54
    anacetrapib - Drug Profile 63
    apabetalone - Drug Profile 65
    AZD-5069 - Drug Profile 77
    AZD-5718 - Drug Profile 79
    beperminogene perplasmid - Drug Profile 80
    Biologics for Acute Coronary Syndrome - Drug Profile 86
    BIS-5409 - Drug Profile 87
    bivalirudin - Drug Profile 88
    cangrelor tetrasodium - Drug Profile 89
    CAP-1002 - Drug Profile 93
    CAP-2003 - Drug Profile 99
    CER-001 - Drug Profile 101
    clopidogrel bisulphate - Drug Profile 105
    COR-2 - Drug Profile 106
    Cryocell - Drug Profile 107
    CSL-112 - Drug Profile 108
    CVBT-141H - Drug Profile 110
    dalcetrapib - Drug Profile 111
    Gemacell - Drug Profile 115
    Gene Therapy to Activate Vascular Endothelial Growth Factor for Coronary Artery Disease - Drug Profile 116
    IONIS-APOARX - Drug Profile 117
    JVS-100 - Drug Profile 120
    MEDI-6012 - Drug Profile 125
    MultiGeneAngio - Drug Profile 128
    MZ-004 - Drug Profile 129
    Neovasculgen - Drug Profile 131
    PC-mAb - Drug Profile 132
    PF-06282999 - Drug Profile 135
    PMC-6 - Drug Profile 136
    PR-15 - Drug Profile 137
    Proteins for Ischemic Heart Disease - Drug Profile 139
    ranolazine ER - Drug Profile 140
    Recombinant Protein for Cardiovascular Diseases - Drug Profile 143
    Rejuveinix - Drug Profile 144
    rivaroxaban - Drug Profile 145
    Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile 161
    Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile 162
    Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 163
    temanogrel hydrochloride - Drug Profile 165
    tirofiban hydrochloride - Drug Profile 167
    TSL-0202 - Drug Profile 168
    vericiguat - Drug Profile 169
    VM-202 - Drug Profile 171
    vonapanitase - Drug Profile 175
    ZK-001 - Drug Profile 180
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 182
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 188
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 190
    Featured News & Press Releases 190
    Appendix 202
    Methodology 202
    Coverage 202
    Secondary Research 202
    Primary Research 202
    Expert Panel Validation 202
    Contact Us 202
    Disclaimer 203

    List of Tables

    Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by advanceCor GmbH, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Akcea Therapeutics Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Arena Pharmaceuticals Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Ascendia Pharmaceuticals LLC, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Athera Biotechnologies AB, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
    1`
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cardiome Pharma Corp, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CSL Ltd, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Esperion Therapeutics Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by HitGen LTD, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Japan Tobacco Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by LipimetiX Development Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune LLC, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pfizer Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pharmahungary Group, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Proteon Therapeutics Inc, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Resverlogix Corp, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Verseon Corp, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by VESSL Therapeutics Ltd, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co Ltd, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017 (Contd..2), H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017 (Contd..3), H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2017
    Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2017 (Contd..1), H1 2017

    List of Figures

    Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    advanceCor GmbH
    Akcea Therapeutics Inc
    Amarantus Bioscience Holdings Inc
    AnGes MG Inc
    Arena Pharmaceuticals Inc
    Ascendia Pharmaceuticals LLC
    AstraZeneca Plc
    Athera Biotechnologies AB
    Bayer AG
    Biscayne Pharmaceuticals Inc
    Capricor Therapeutics Inc
    Cardiome Pharma Corp
    CardioVascular BioTherapeutics Inc
    Cerenis Therapeutics Holding SA
    CSL Ltd
    Esperion Therapeutics Inc
    Gilead Sciences Inc
    HitGen LTD
    Human Stem Cells Institute
    Japan Tobacco Inc
    Juventas Therapeutics Inc
    Lee's Pharmaceutical Holdings Ltd
    LipimetiX Development Inc
    Lonestar Heart Inc
    MedImmune LLC
    Merck & Co Inc
    Nuo Therapeutics Inc
    Pfizer Inc
    Pharmahungary Group
    Proteon Therapeutics Inc
    Resverlogix Corp
    Tasly Pharmaceutical Group Co Ltd
    The Medicines Company
    Verseon Corp
    VESSL Therapeutics Ltd
    ViroMed Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments